PHRX / Pharmagen, Inc. - SEC备案- 年度报告、委托书

法玛根公司
US ˙ OTCPK

基本统计
CIK 1470915
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pharmagen, Inc.
SEC Filings (Chronological Order)
本页提供了美国证券交易委员会(SEC)备案的完整、按时间顺序排列的列表,不包括我们在其他地方提供的所有权备案。
August 7, 2014 15-12G

PHRX / Pharmagen, Inc. 15-12G - - 15-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-54523 Pharmagen, Inc. (Exact name of registrant as specified in its char

July 17, 2014 SC 13G/A

PHRX / Pharmagen, Inc. / IBC FUNDS LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Amendment Number 1 Under the Securities Exchange Act of 1934 PHARMAGEN, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 71715W 106 (CUSIP number) February 18, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

July 17, 2014 SC 13G

PHRX / Pharmagen, Inc. / IBC FUNDS LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PHARMAGEN, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 71715W 106 (CUSIP number) August 30, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

July 2, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporatio

June 24, 2014 EX-10.1

FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT

EXHIBIT 10.1 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (“Agreement”) is entered into effective June 18, 2014, (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Boyd P. Relac, an individual (the “Executive”). WHEREAS, the Company and the Executive entered into that certain Employment Agreement

June 24, 2014 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number

June 18, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number)

June 13, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation

June 13, 2014 EX-10.1

EMPLOYMENT AGREEMENT

EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is entered into effective June 9, 2014, (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Russell Skibsted, an individual (the “Executive”). NOW, THEREFORE, in consideration of the mutual covenants set forth below, the parties agree as follows: ARTICLE 1. DUTIES AND SCOPE OF EMP

June 11, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number

June 4, 2014 SC 13D

PHRX / Pharmagen, Inc. / Wolpow Richard - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Pharmagen, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71715W 106 (CUSIP Number) Richard A. Wolpow 9337 Fraser Avenue Silver Spring, MD 20910 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicati

June 3, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number)

June 3, 2014 EX-99.1

Pharmagen Appoints Additional Members to its Board of Directors

EXHIBIT 99.1 Pharmagen Appoints Additional Members to its Board of Directors SILVER SPRING, Md., May 29, 2014 /PRNewswire via COMTEX/ - Pharmagen, Inc. (OTCPink: PHRX) (the “Company” or “Pharmagen”) announces that effective June 1, 2014, it has appointed three additional members to its Board of Directors, which now consists of five (5) members. Under its agreement with Bagel Boy Equity Group II, L

May 22, 2014 8-K

Financial Statements and Exhibits, Other Events

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation

May 21, 2014 EX-10.1

EMPLOYMENT AGREEMENT

EX-10.1 2 phrxex101.htm EMPLOYMENT AGREEMENT EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is entered effective April 1, 2014, (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Boyd P. Relac, an individual (the “Executive”). Now therefore, in consideration of the mutual covenants set forth below, the parties agree as follow

May 21, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number

May 15, 2014 10-Q

Quarterly Report - FORM 10-Q

10-Q 1 phrx10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file

May 15, 2014 EX-10.12

1

EX-10.12 2 phrxex1012.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.12 1 2 3

April 4, 2014 8-K

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporatio

March 31, 2014 10-K

Annual Report - FORM 10-K

10-K 1 phrx10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-545

March 25, 2014 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporati

March 25, 2014 EX-10.1

CONSULTING SERVICES AGREEMENT

EX-10.1 2 phrxex101.htm CONSULTING SERVICES AGREEMENT EXHIBIT 10.1 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (this “Agreement”) is made and entered into on March 1, 2014 (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company” or “Client”), and Stylinz Industries, Inc., a Wyoming Corporation (the “Consultant”). Each of the Company and the Co

March 25, 2014 EX-10.2

PHARMAGEN, INC.

EXHIBIT 10.2 PHARMAGEN, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO TH

March 21, 2014 EX-10.1

SETTLEMENT AND RELEASE AGREEMENT

EX-10.1 2 phrxex101.htm SETTLEMENT AND RELEASE AGREEMENT EXHIBIT 10.1 SETTLEMENT AND RELEASE AGREEMENT THIS SETTLEMENT AND RELEASE AGREEMENT (the “Agreement”), dated March 14, 2014 (the “Effective Date”), is made by and among (i) PHARMAGEN, INC., a corporation incorporated under the laws of the State of Nevada and formerly known as Sunpeaks Ventures, Inc. (the “Plaintiff”), (ii) PHARMAGEN DISTRIBU

March 21, 2014 8-K

Entry into a Material Definitive Agreement

8-K 1 phrx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporati

March 21, 2014 EX-10.2

CONSOLIDATED, AMENDED AND RESTATED PROMISSORY NOTE Effective Date: March 14, 2014 US$2,433,182.68

EX-10.2 3 phrxex102.htm CONSOLIDATED, AMENDED AND RESTATED EXHIBIT 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMEN

February 28, 2014 EX-10.1

ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE $180,000 February 24, 2014

EX-10.1 3 phrxex101.htm ORIGINAL ISSUE DISCOUNT PROMISSORY EXHIBIT 10.1 ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE $180,000 February 24, 2014 For value received, Pharmagen, Inc., a Nevada corporation (the “Borrower”), promises to pay to Network Ventures, LLC, or its assigns (the “Holder”) the principal sum of One Hundred Eighty Thousand Dollars ($180,000) (the “Principal Amount”). The principal hereo

February 28, 2014 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Nu

February 28, 2014 EX-3.1

CERTIFICATE OF AMENDMENT ARTICLES OF INCORPORATION PHARMAGEN, INC. (Pursuant to NRS 78.385 and 78.390 – after issuance of stock)

EX-3.1 2 phrxex31.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION OF PHARMAGEN, INC. (Pursuant to NRS 78.385 and 78.390 – after issuance of stock) The undersigned being the President and Secretary of Pharmagen, Inc., a Nevada Corporation (the “Corporation”), hereby certifies that pursuant to Unanimous Written Consent of the Board of Directors of the C

February 28, 2014 EX-10.2

Pharmagen, Inc. SECURITIES PURCHASE AGREEMENT 2,000,000 shares Common Stock $0.01 per share

EX-10.2 4 phrxex102.htm SECURITIES PURCHASE AGREEMENT EXHIBIT 10.2 Pharmagen, Inc. SECURITIES PURCHASE AGREEMENT 2,000,000 shares of Common Stock $0.01 per share Page 1 of 11 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into on February 24, 2014 (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Network

February 24, 2014 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2014 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Nu

January 2, 2014 DEF 14A

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

December 20, 2013 EX-10.1

PHARMAGEN, INC. SECURITIES EXCHANGE AGREEMENT

EXHIBIT 10.1 PHARMAGEN, INC. SECURITIES EXCHANGE AGREEMENT 1 SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “Agreement”) is entered into on December 16, 2013 (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Old Line Partners, LLC, a Nevada limited liability company (the “Shareholder”). The Company and Shareholder shall each be

December 20, 2013 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Nu

December 20, 2013 EX-4.1

CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES B “MANAGEMENT-CLASS” CONVERTIBLE PREFERRED STOCK PHARMAGE

EXHIBIT 4.1 CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES B “MANAGEMENT-CLASS” CONVERTIBLE PREFERRED STOCK OF PHARMAGEN, INC. The undersigned, Mackie Barch, does hereby certify that: A. He is the President and Secretary of Pharmagen, Inc., a Nevada corp

December 20, 2013 PRE 14A

- PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

December 16, 2013 EX-10.4

Pharmagen, Inc. SECURITIES PURCHASE AGREEMENT Up to 500,000 shares Series C Convertible Preferred Stock $1.00 per share Up to $500,000

EX-10.4 6 phrxex104.htm FORM OF SECURITIES PURCHASE AGREEMENT EXHIBIT 10.4 Pharmagen, Inc. SECURITIES PURCHASE AGREEMENT Up to 500,000 shares of Series C Convertible Preferred Stock $1.00 per share Up to $500,000 1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into on December [insert], 2013 (the “Effective Date”) by and between Pharmagen, Inc., a N

December 16, 2013 EX-10.1

PHARMAGEN, INC. CONSULTING SERVICES AGREEMENT

EXHIBIT 10.1 PHARMAGEN, INC. CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (this “Agreement”) is entered into on December 9, 2013 (the “Effective Date”) by and between Pharmagen, Inc., a Nevada corporation (the “Company”), and Bagel Boy Equity Group II, LLC, a Nevada limited liability company (the “Consultant”). Each of the Company and the Consultant shall be referred to individ

December 16, 2013 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Nu

December 16, 2013 EX-4.2

CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES C CONVERTIBLE PREFERRED STOCK PHARMAGEN, INC.

EXHIBIT 4.2 CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES C CONVERTIBLE PREFERRED STOCK OF PHARMAGEN, INC. The undersigned, Mackie Barch, does hereby certify that: A. He is the President and Secretary of Pharmagen, Inc., a Nevada corporation (the “Corpo

December 16, 2013 EX-10.3

PHARMAGEN, INC.

EX-10.3 5 phrxex103.htm COMMON STOCK CONSULTING WARRANT EXHIBIT 10.3 PHARMAGEN, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT

December 16, 2013 EX-10.2

PHARMAGEN, INC.

EXHIBIT 10.2 PHARMAGEN, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO TH

November 14, 2013 10-Q

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-54523 Pharma

September 10, 2013 EX-10.2

IN THE CIRCUIT COURT IN THE TWELFTH JUDICIAL CIRCUIT IN AND FOR SARASOTA COUNTY, FLORIDA

EX-10.2 3 phrx102.htm ORDER GRANTING APPROVAL OF SETTLEMENT AGREEMENT EXHIBIT 10.2 IN THE CIRCUIT COURT IN THE TWELFTH JUDICIAL CIRCUIT IN AND FOR SARASOTA COUNTY, FLORIDA CIVIL ACTION NO. IBC Funds, LLC, a Nevada Limited Liability Corporation, Plaintiff, -against- Pharmagen, Inc., a Nevada Corporation, Defendant. / ORDER GRANTING APPROVAL OF SETTLEMENT AGREEMENT This matter having come on for a h

September 10, 2013 EX-10.1

SETTLEMENT AGREEMENT AND STIPULATION

EX-10.1 2 phrx101.htm SETTLEMENT AGREEMENT EXHIBIT 10.1 SETTLEMENT AGREEMENT AND STIPULATION THIS SETTLEMENT AGREEMENT and Stipulation dated as of , 2013 by and between Pharmagen, Inc. (“Pharmagen” or the “Company”), a corporation formed under the laws of the State of Nevada, and IBC Funds, LLC (“IBC”), a Nevada Limited Liability Company. BACKGROUND: WHEREAS, there are bona fide outstanding liabil

September 10, 2013 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Nu

August 15, 2013 8-K

Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Numbe

August 15, 2013 EX-10.1

SECURITIES PURCHASE AGREEMENT

EX-10.1 2 pharmagenex101.htm SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 1, 2013, by and between PHARMAGEN, INC., a Nevada corporation, with headquarters located at 9337 Fraser Avenue, Silver Spring, MD 20910 (the “Company”), and ASHER ENTERPRISES, INC., a Delaware corporation, with its address at

August 15, 2013 EX-10.2

Principal Amount: $42,500.00 Issue Date: August 1, 2013 Purchase Price: $42,500.00 CONVERTIBLE PROMISSORY NOTE

EX-10.2 3 pharmagenex102.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN TH

August 14, 2013 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One)

10-Q 1 phrx10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file

July 12, 2013 EX-10.1

CONSULTING AGREEMENT

EXHIBIT 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT is made this 1st day of July , 2013, by and between PHARMAGEN, INC., (hereinafter referred to as the “Company"), and BRADLEY PEGANOFF (hereinafter referred to as the "Consultant"). EXPLANATORY STATEMENT A. The Company is meeting the demands of the health provider market as a distributor of specialty drugs, compounding and admix pharmacy a

July 12, 2013 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission File Number)

June 25, 2013 EX-10.2

Principal Amount: $63,000.00 Issue Date: June 5, 2013 Purchase Price: $63,000.00

EX-10.2 3 pharmagenex102.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN TH

June 25, 2013 8-K

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 pharmagen8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorpo

June 25, 2013 EX-10.1

SECURITIES PURCHASE AGREEMENT

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 5, 2013, by and between PHARMAGEN, INC., a Nevada corporation, with headquarters located at 9337 Fraser Avenue, Silver Spring, MD 20910 (the “Company”), and ASHER ENTERPRISES, INC., a Delaware corporation, with its address at 1 Linden Place, Suite 207, Great Neck, NY 11021 (the “Buyer”

May 15, 2013 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-54523 Pharmagen,

May 10, 2013 RW

- RW

Pharmagen, Inc. 9337 Fraser Avenue Silver Spring, MD 20910 May 10, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Pamela Howell Re: Pharmagen, Inc. Registration Statement on Form S-1 File No. 333-186188 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, we hereby request the wit

April 12, 2013 EX-10.14

SECURITY AGREEMENT

EX-10.14 15 pharmagenex1014.htm SECURITY AGREEMENT FOR PHARMAGEN NUTRICEUTICALS, INC. EXHIBIT 10.14 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of March 29, 2013 (as may be amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN NUTRICEUTICALS, INC., a corporation incorporated under the laws of the State of Delaware (the “

April 12, 2013 EX-10.18

CONSENT AND AGREEMENT TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT

EX-10.18 19 pharmagenex1018.htm SUBSIDIARY CONSENT FOR PHARMAGEN LABORATORIES, INC. EXHIBIT 10.18 CONSENT AND AGREEMENT TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT Reference is made to that certain Senior Secured Revolving Credit Facility Agreement, dated as of September 30, 2012, as amended by Amendment No. 1 thereto, dated November 30, 2012 (as amended and as may hereafter be amended o

April 12, 2013 EX-10.20

CONSENT AND AGREEMENT TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT

EXHIBIT 10.20 CONSENT AND AGREEMENT TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT Reference is made to that certain Senior Secured Revolving Credit Facility Agreement, dated as of September 30, 2012, as amended by Amendment No. 1 thereto, dated November 30, 2012 (as amended and as may hereafter be amended or restated from time to time, the “Credit Agreement”), made by and among (i) Pharmag

April 12, 2013 EX-10.3

SECURITY AGREEMENT

EXHIBIT 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of February 28, 2013 (as amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN, INC., a corporation incorporated under the laws of the State of Nevada, whose address is 9337 Fraser Avenue, Silver Spring, MD 20910 (the “Grantor”), and TCA GLOBAL CREDIT MASTER FUND,

April 12, 2013 EX-10.15

SECURITY AGREEMENT

EX-10.15 16 pharmagenex1015.htm SECURITY AGREEMENT FOR PHARMAGEN LABORATORIES, INC. EXHIBIT 10.15 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of March 29, 2013 (as may be amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN LABORATORIES, INC., a corporation incorporated under the laws of the State of New York and former

April 12, 2013 EX-10.6

SECURITY AGREEMENT

EX-10.6 7 pharmagenex106.htm SECURITY AGREEMENT FOR PHARMAGEN LABORATORIES, INC. EXHIBIT 10.6 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of February 28, 2013 (as amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN LABORORATORIES, INC., a corporation incorporated under the laws of the State of New York, whose address i

April 12, 2013 EX-10.4

SECURITY AGREEMENT

EXHIBIT 10.4 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of February 28, 2013 (as amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN DISTRIBUTION, LLC, a limited liability company organized and existing under the laws of the State of Delaware, whose address is 9337 Fraser Avenue, Silver Spring, MD 20910 (the “Grantor”

April 12, 2013 EX-10.13

AMENDMENT NO. 2 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG PHARMAGEN, INC., as Borrower, PHARMAGEN DISTRIBUTION, LLC, PHARMAGEN LABORATORIES, INC. PHARMAGEN NUTRICEUTICALS, INC. as Joint and Several

EXHIBIT 10.13 AMENDMENT NO. 2 TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG PHARMAGEN, INC., as Borrower, PHARMAGEN DISTRIBUTION, LLC, PHARMAGEN LABORATORIES, INC. PHARMAGEN NUTRICEUTICALS, INC. as Joint and Several Guarantors, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender March 29, 2013 1 AMENDMENT NO. 2 TO SENIOR SECURED REVOLVING CREDIT FACI

April 12, 2013 EX-10.17

GUARANTY AGREEMENT

EX-10.17 18 pharmagenex1017.htm GUARANTY AGREEMENT FOR PHARMAGEN LABORATORIES, INC. EXHIBIT 10.17 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT is dated as of March 29, 2013 (as amended, restated or modified from time to time, the “Guaranty”), and is made by PHARMAGEN LABORATORIES, INC., a corporation incorporated under the laws of the State of New York and formerly known as BryceRx Laboratories, Inc

April 12, 2013 EX-10.7

GUARANTY AGREEMENT

EX-10.7 8 pharmagenex107.htm GUARANTY AGREEMENT FOR PHARMAGEN DISTRIBUTION, LLC EXHIBIT 10.7 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT is dated as of February 28, 2013 (as amended, restated or modified from time to time, the “Guaranty”), and is made by PHARMAGEN DISTRIBUTION, LLC, a limited liability company organized and existing under the laws of the State of Delaware and formerly known as Heal

April 12, 2013 EX-10.19

CONSENT AND AGREEMENT TO AMENDED AND RESTATED REVOLVING PROMISSORY NOTE

EX-10.19 20 pharmagenex1019.htm SUBSIDIARY CONSENT FOR PHARMAGEN LABORATORIES, INC. EXHIBIT 10.19 CONSENT AND AGREEMENT TO AMENDED AND RESTATED REVOLVING PROMISSORY NOTE Reference is made to that certain Amended and Restated Revolving Promissory Note, issued by the Borrower in favor of the Lender, as of November 30, 2012 and effective as of December 12, 2012 (as amended and as may hereafter be ame

April 12, 2013 EX-10.11

IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT

EXHIBIT 10.11 IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT THIS IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT (as amended, restated and modified from time to time, the “Agreement”) is made and entered into as of this 28TH day of February, 2013, by and among PHARMAGEN, INC., a corporation incorporated under the law

April 12, 2013 EX-10.10

DATED this ____day of ___________, 20___. BY THE COURT ___________________________________

EX-10.10 11 pharmagenex1010.htm CONFESSION OF JUDGMENT EXHIBIT 10.10 () Telephone: () Facsimile: () Attorney for TCA Global Credit Master Fund, LP TCA GLOBAL CREDIT MASTER FUND, LP, a Cayman Island limited partnership, Plaintiff, vs. PHARMAGEN, INC., a Nevada corporation, and PHARMAGEN DISTRIBUTION, LLC, a Delaware limited liability company, PHARMAGEN LABORATORIES, INC., a New York corporation, an

April 12, 2013 EX-10.16

GUARANTY AGREEMENT

EXHIBIT 10.16 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT is dated as of March 29, 2013 (as amended, restated or modified from time to time, the “Guaranty”), and is made by PHARMAGEN NUTRICEUTICALS, INC., a corporation incorporated under the laws of the State of Delaware (the “Guarantor”), in favor of TCA GLOBAL CREDIT MASTER FUND, LP, a limited partnership organized and existing under the laws of

April 12, 2013 EX-10.12

VALIDITY GUARANTY

EX-10.12 13 pharmagenex1012.htm VALIDITY GUARANTEE EXHIBIT 10.12 VALIDITY GUARANTY This Validity Guaranty, dated as February 28, 2013 (as amended, restated or modified from time to time, the “Validity Guaranty”), is made by MACKIE BARCH (the “Guarantor”), for the benefit of TCA GLOBAL CREDIT MASTER FUND, LP, a limited partnership organized and existing under the laws of the Cayman Islands (the “Le

April 12, 2013 EX-10.9

GUARANTY AGREEMENT

EXHIBIT 10.9 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT is dated as of February 28, 2013 (as amended, restated or modified from time to time, the “Guaranty”), and is made by PHARMAGEN LABORATORIES, INC., a corporation incorporated under the laws of the State of New York and formerly known as BryceRx Laboratories, Inc. (the “Guarantor”), in favor of TCA GLOBAL CREDIT MASTER FUND, LP, a limited part

April 12, 2013 EX-10.21

CONSENT AND AGREEMENT TO AMENDED AND RESTATED REVOLVING PROMISSORY NOTE

EX-10.21 22 pharmagenex1021.htm SUBSIDIARY CONSENT FOR PHARMAGEN NUTRICEUTICALS, INC. EXHIBIT 10.21 CONSENT AND AGREEMENT TO AMENDED AND RESTATED REVOLVING PROMISSORY NOTE Reference is made to that certain Amended and Restated Revolving Promissory Note, issued by the Borrower in favor of the Lender, as of November 30, 2012 and effective as of December 12, 2012 (as amended and as may hereafter be a

April 12, 2013 EX-10.1

SENIOR SECURED CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$2,000,000 BY AND AMONG PHARMAGEN, INC., as Borrower, PHARMAGEN DISTRIBUTION, LLC, PHARMAGEN LABORATORIES, INC. PHARMAGEN NUTRICEUTICALS, INC. as Joint and Several Guarantors, TCA GLOBAL CRE

EX-10.1 2 pharmagenex101.htm SENIOR SECURED CREDIT FACILITY AGREEMENT EXHIBIT 10.1 SENIOR SECURED CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$2,000,000 BY AND AMONG PHARMAGEN, INC., as Borrower, PHARMAGEN DISTRIBUTION, LLC, PHARMAGEN LABORATORIES, INC. PHARMAGEN NUTRICEUTICALS, INC. as Joint and Several Guarantors, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender February 28, 2013 SENIOR SECURED

April 12, 2013 EX-10.2

CONVERTIBLE PROMISSORY NOTE Issuance Date: February 28, 2013 US$600,000 Effective Date: March 29, 2013

EXHIBIT 10.2 NEITHER THIS NOTE NOR THE SECURITIES THAT ARE ISSUABLE TO THE HOLDER UPON CONVERSION HEREOF (COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED

April 12, 2013 8-K/A

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2013 PHARMAGEN, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (C

April 12, 2013 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2013 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission Fi

April 12, 2013 EX-10.5

SECURITY AGREEMENT

EXHIBIT 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of February 28, 2013 (as amended, restated or modified from time to time, the “Security Agreement”), is executed by and between PHARMAGEN NUTRICEUTICALS, INC., a corporation incorporated under the laws of the State of Delaware, whose address is 9337 Fraser Avenue, Silver Spring, MD 20910 (the “Grantor”), and TCA GLOBAL CRE

April 12, 2013 EX-10.8

GUARANTY AGREEMENT

EX-10.8 9 pharmagenex108.htm GUARANTY AGREEMENT FOR PHARMAGEN NUTRICEUTICALS, INC. EXHIBIT 10.8 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT is dated as of February 28, 2013 (as amended, restated or modified from time to time, the “Guaranty”), and is made by PHARMAGEN NUTRICEUTICALS, INC., a corporation incorporated under the laws of the State of Delaware (the “Guarantor”), in favor of TCA GLOBAL CR

April 1, 2013 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54523 Pharmagen, Inc. (Exact n

January 25, 2013 S-1

Registration Statement - FORM S-1

As filed with the Securities and Exchange Commission on January 25, 2013 Registration No.

January 25, 2013 EX-21

Subsidiaries of the Registrant

Exhibit 21 Subsidiaries of the Registrant Pharmagen Laboratories, Inc. Pharmagen Distribution, LLC

January 25, 2013 EX-99.1

Unaudited Pro Forma Condensed Combined Financial Statements

Exhibit 99.1 Unaudited Pro Forma Condensed Combined Financial Statements On February 16, 2012, pursuant to a Share Exchange Agreement (“Exchange Agreement”) dated February 13, 2012, Sunpeaks acquired 100% ownership interest in Healthcare Distribution Specialists LLC (“HDS”), a Delaware limited liability company, in exchange for the issuance of 200,000,000 newly-issued restricted shares of Sunpeaks

January 14, 2013 EX-3.01

ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov Filed in the office of Document Number Ross Miller Secretary of State State of Nevada 20120874787-86 Certificate of A

EX-3.01 2 sunpeaksex301.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.01 ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov Filed in the office of Document Number Ross Miller Secretary of State State of Nevada 20120874787-86 Certificate of Amendment (PURSUANT TO NRS 78,385 AND 78,390) Filing Date and Time 12/28/2012 10:47 A

January 14, 2013 8-K

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission

January 11, 2013 SC 13D

PHRX / Pharmagen, Inc. / OLD LINE PARTNERS LLC - SC 13D Activist Investment

SC 13D 1 oldlinesc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Sunpeaks Ventures, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86765E202 (CUSIP Number) Brian A. Lebrecht, Esq. The Lebrecht Group, APLC 406 W. South Jordan Parkway, Suite 160 South Jordan, UT 84095 (8

January 7, 2013 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission

January 3, 2013 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 snpk8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of

January 3, 2013 EX-10.1

WALGREEN CO. GENERAL TRADE AND ELECTRONIC DATA INTERCHANGE AGREEMENT SIGNATURE PAGE

EXHIBIT 10.1 WALGREEN CO. GENERAL TRADE AND ELECTRONIC DATA INTERCHANGE AGREEMENT SIGNATURE PAGE The Walgreen Co. General Trade Electronic Data Interchange Agreement (“Agreement”) attached hereto is by and between Walgreen Co., on behalf of itself and its U.S. domestic and Puerto Rico subsidiaries and affiliates, (collectively, “Walgreen”) and the company named below (“Vendor”). Vendor’s authorize

December 19, 2012 EX-2.1

STOCK PURCHASE AGREEMENT

EX-2.1 2 snpkex21.htm STOCK PURCHASE AGREEMENT EXHIBIT 2.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT is made and entered into as of the 13th day of December, 2012, by and between Robert Giuliano, individual (“Seller”), Bryce Rx Laboratories, Inc., a New York corporation (“Company”), and Sunpeaks Ventures, Inc., a Nevada corporation (“Purchaser”). EXPLANATORY STATEMENT A. Seller owns a

December 19, 2012 EX-10.1

ROBERT GIULIANO EMPLOYMENT AGREEMENT

EXHIBIT 10.1 ROBERT GIULIANO EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated December 13, 2012 (?Effective Date?), is between Bryce Rx Laboratories, Inc. (?Company?) and Robert Giuliano (?Employee?). WITNESSETH: WHEREAS, on the Effective Date, all of the outstanding shares of stock of the Company were sold to Sunpeaks Ventures, Inc.; WHEREAS, Employee has been employed by Company before the

December 19, 2012 EX-10.2

RESTRICTIVE COVENANT AGREEMENT

EX-10.2 4 snpkex102.htm RESTRICTIVE COVENANT AGREEMENT EXHIBIT 10.2 RESTRICTIVE COVENANT AGREEMENT This Agreement is made and delivered by me, Robert Giuliano (“me” or “I”), as an employee of the Bryce Rx Laboratories, Inc., (“Company”). This Agreement is effective on the date I sign it. I understand that this Agreement applies throughout my employment with the Company and that certain provisions

December 19, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission

December 17, 2012 EX-10.1

COMMITTED EQUITY FACILITY AGREEMENT

EX-10.1 2 snpkex101.htm COMMITTED EQUITY FACILITY AGREEMENT EXHIBIT 10.1 COMMITTED EQUITY FACILITY AGREEMENT This Committed Equity Facility Agreement (the “Agreement”) is dated as of the 30th day of November, 2012, by and between TCA GLOBAL CREDIT MASTER FUND, LP, a Cayman Islands limited partnership (the “Investor”) and SUNPEAKS VENTURES, INC., a Nevada corporation (the “Company”). RECITALS WHERE

December 17, 2012 EX-10.5

IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT

EXHIBIT 10.5 IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT THIS IRREVOCABLE TRANSFER AGENT INSTRUCTION AND TRANSFER AGENT ACKNOWLEDGEMENT AND AGREEMENT (as amended, restated and modified from time to time, the “Agreement”) is made and entered into as of this 12th day of December, 2012, by and among SUNPEAKS VENTURES, INC., a corporation incorporated under

December 17, 2012 8-K/A

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K/A2 AMENDED CURRENT REPORT

FORM 8-K/A2 Amended Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

December 17, 2012 EX-10.3

AMENDMENT NO. 1 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC as Guarantor, TCA GLOBAL CREDIT MASTER FUND, LP, as Lender Nov

EXHIBIT 10.3 AMENDMENT NO. 1 TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC as Guarantor, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender November 30, 2012 AMENDMENT NO. 1 TO SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT THIS AMENDMENT NO. 1 TO SENIOR SECURED REVOLV

December 17, 2012 EX-10.4

AMENDED AND RESTATED REVOLVING PROMISSORY NOTE Issuance Date: November 30, 2012 US$1,450,000 Effective Date: December 12, 2012

EXHIBIT 10.4 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARD RESALE AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITI

December 17, 2012 CORRESP

-

Sunpeaks SEC Comment Response to 12.5.12 letter (00057917).DOC THE LEBRECHT GROUP A PROFESSIONAL LAW CORPORATION Brian A. Lebrecht, Esq.* *Admitted in California and Utah December 14, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Pamela Howell Re: Sunpeaks Ventures, Inc. Amendment no. 3 to Current Report on Form

December 17, 2012 EX-10.1

SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012

EX-10.1 2 f8ka2121312ex10z1.htm EXHIBIT 10.1 SENIOR FACILITY AGREEMENT Exhibit 10.1 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012 - 1 - SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT This

December 17, 2012 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction of incorporation) (Commission

December 17, 2012 EX-10.2

REGISTRATION RIGHTS AGREEMENT

EX-10.2 3 snpkex102.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is dated as of the 30th day of November, 2012, and made effective as of the “Effective Date” (as defined in the CEF Agreement), by and between SUNPEAKS VENTURES, INC., a Nevada corporation (the “Company”) and TCA GLOBAL CREDIT MASTER FUND, LP, a Caym

November 21, 2012 EX-10.1

SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012

Exhibit 10.1 Senior Facility Agreement Exhibit 10.1 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012 - 1 - SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT This SENIOR SECURED REVOLVING CREDIT

November 21, 2012 8-K/A

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K/A AMENDED CURRENT REPORT

FORM 8-K/A Amended Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

November 21, 2012 8-K/A

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets - FORM 8-K/A3 AMENDED CURRENT REPORT

FORM 8-K/A3 Amended Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.

November 21, 2012 EX-10.2

HDS/AACSA Marketing & Distribution Agreement

EX-10.2 2 f8ka112012ex10z2.htm EXHIBIT 10.2 MARKETING AND DISTRIBUTION AGREEMENT Exhibit 10.2 HDS/AACSA Marketing & Distribution Agreement 1. Overview: Asian American Convenience Store Association ("AACSA") shall coordinate with Health Care Distribution Specialists, LLC ("HDS") to confer with AACSA PARTNERS as fully set forth in Exhibit A attached hereto and incorporated herein by this reference.

November 21, 2012 8-K/A

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K/A AMENDED CURRENT REPORT

FORM 8-K/A Amended Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

November 21, 2012 CORRESP

-

November 21, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

November 21, 2012 8-K/A

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Second Amended Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commissi

November 19, 2012 DEF 14A

- DEFINITIVE 14A PROXY STATEMENT

Definitive 14A Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

November 14, 2012 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-54523 SUNPEA

November 6, 2012 PRE 14A

- PRELIMINARY 14A

Preliminary 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant X . Filed by a Party other than the Registrant . Check the appropriate box: X . Preliminary Proxy Statement . Confidential, for Use of the Commission Only (as permit

November 2, 2012 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 2 (Mark One) X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 0

October 18, 2012 EX-99.2

Unaudited Pro Forma Condensed Combined Financial Statements

EX-99.2 3 f8ka101712ex99z2.htm EXHIBIT 99.2 PRO FORMA FINANCIAL STATEMENTS Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Statements On February 16, 2012, pursuant to a Share Exchange Agreement (“Exchange Agreement”) dated February 13, 2012, Sunpeaks acquired 100% ownership interest in Healthcare Distribution Specialists LLC (“HDS”), a Delaware limited liability company, in exchange

October 18, 2012 8-K/A

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction (Commission File Number) (IRS Employer of

October 18, 2012 EX-99.1

Healthcare Distribution Specialists, Inc. (formerly Amerisure Pharmaceuticals LLC) Financial Statements For the Years Ended December 31, 2011 and 2010 (Adjusted) Page Report of Independent Registered Public Accounting Firm 2 Consolidated Balance Shee

Exhibit 99.1 Audited Consolidated Financials Exhibit 99.1 Healthcare Distribution Specialists, Inc. (formerly Amerisure Pharmaceuticals LLC) Financial Statements For the Years Ended December 31, 2011 and 2010 (Adjusted) Page Report of Independent Registered Public Accounting Firm 2 Consolidated Balance Sheet as of December 31, 2011 and Combined Balance Sheet as of December 31, 2010 3 Consolidated

October 17, 2012 CORRESP

-

SEC Response October 17, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

October 17, 2012 EX-10.3

SECURITY AGREEMENT

EX-10.3 4 f8k101612ex10z3.htm EXHIBIT 10.3 SECURITY AGREEMENT SUNPEAK VENTURES Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of September 30, 2012 (as amended, restated or modified from time to time, the “Security Agreement”), is executed by and between SUNPEAKS VENTURES, INC., a corporation incorporated under the laws of the State of Nevada (the “Grantor”), and TCA G

October 17, 2012 EX-10.1

SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012

Exhibit 10.1 Senior Facility Agreement Exhibit 10.1 SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT IN THE AMOUNT OF US$5,000,000 BY AND AMONG SUNPEAKS VENTURES, INC., as Borrower, HEALTHCARE DISTRIBUTION SPECIALISTS LLC, as Guarantor, AND TCA GLOBAL CREDIT MASTER FUND, LP, as Lender September 30, 2012 - 1 - SENIOR SECURED REVOLVING CREDIT FACILITY AGREEMENT This SENIOR SECURED REVOLVING CREDIT

October 17, 2012 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT

FORM 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

October 17, 2012 EX-10.2

REVOLVING PROMISSORY NOTE

Exhibit 10.2 Revolving Note Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARD RESALE AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATIO

October 17, 2012 EX-10.4

SECURITY AGREEMENT

Exhibit 10.4 Security Agreement Healthcare Dist Exhibit 10.4 SECURITY AGREEMENT This SECURITY AGREEMENT, dated effective as of September 30, 2012 (as may be amended, restated or modified from time to time, the “Security Agreement”), is executed by and between HEALTHCARE DISTRIBUTION SPECIALISTS LLC, a limited liability company organized and existing under the laws of the State of Delaware (the “Gr

October 12, 2012 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commission Fil

October 12, 2012 EX-10.1

EMPLOYMENT AGREEMENT

EX-10.1 2 f8k101112ex10z1.htm EXHIBIT 10.1 EMPLOYEE AGREEMENT EMPLOYMENT AGREEMENT This Employment Agreement is entered this 9th day of October, 2012, by and between Sunpeaks Ventures, Inc., a Nevada corporation (the “Employer”), and Mackie Barch, an individual, hereinafter referred to as “Employee,” in consideration of the mutual promises made herein, agree as follows: ARTICLE 1. TERM OF EMPLOYME

September 14, 2012 CORRESP

-

THE LEBRECHT GROUP A PROFESSIONAL LAW CORPORATION Brian A. Lebrecht, Esq. Craig V. Butler, Esq. * Admitted only in California* September 13, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Ruairi Regan Re: Sunpeaks Ventures, Inc. (the “Company”) Current Report on Form 8-K Filed February 17, 2012 File No. 000-54523

September 14, 2012 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 0

August 14, 2012 EX-10.15

ADVERTISING AND PROMOTION AGREEMENT

EX-10.15 5 f10q063012ex10z15.htm EXHIBIT 10.15 AZ CARDINALS AGREEMENT Exhibit 10.15 ADVERTISING AND PROMOTION AGREEMENT This Advertising and Promotion Agreement ("Agreement") is entered into as of April ·11, 2012, by and among Healthcare Distribution Specialists ("Sponsor”), New Cardinals Stadium, LLC and Arizona Cardinals Football Club LLC. New Cardinals Stadium, LLC and Arizona Cardinals Footbal

August 14, 2012 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-54523 SUNPEAKS

August 14, 2012 EX-10.13

PASS-THROUGH SPONSORSHIP L.EITER AGREEM.ENT

EX-10.13 3 f10q063012ex10z13.htm EXHIBIT 10.13 PASS THROUGH AGREEMENT TRAILBLAZER Exhibit 10.13 PASS-THROUGH SPONSORSHIP L.EITER AGREEM.ENT The parties to this Agreement are TRAIL BLAZERS INC. ("Trail Blazers” or "TBI") and Healthcare Distribution Specialists ("Advertiser"). TBI is executing this Agreement on its own behalf as to the inventory that TBI owns and as agent for Rip City Management LLC

August 14, 2012 EX-10.16

BINDING LETTER OF COMMITMENT

EX-10.16 6 f10q063012ex10z16.htm EXHIBIT 10.16 BURT REYNOLDS SOVERIGN TALENT AGREE Exhibit 10.16 BINDING LETTER OF COMMITMENT THIS BINDING LETTER OF COMMITMENT ("Commitment") is entered into as of April 19th, 2012 by SOVEREIGN TALENT GROUP, Inc (the "Team") located at 8421 Wilshire Blvd, Suite 200, Beverly Hills, CA 90211, and Healthcare Distribution Specialists "CLOTAMIN" located at 9337 Fraser A

August 14, 2012 EX-10.14

THIS BINDING LETTER OF COMMITMENT (“Commitment”) is entered into as of April 24, 2012 by THE PHILADELPHIA SOUL (the “Team”), and Healthcare Distribution Specialists “CLOTAMIN" ("Vendor").

EX-10.14 4 f10q063012ex10z14.htm EXHIBIT 10.14 PHILADELPHIA SOUL AGREEMENT Exhibit 10.14 THIS BINDING LETTER OF COMMITMENT (“Commitment”) is entered into as of April 24, 2012 by THE PHILADELPHIA SOUL (the “Team”), and Healthcare Distribution Specialists “CLOTAMIN" ("Vendor"). Description of Vendor Participation Program Team-Walgreens joint marketing program whereby Walgreens will offer certain ven

August 14, 2012 EX-10.20

Marketing & Sponsorship Contract MARKETING & SPONSORSHIP AGREEMENT

Sunpeaks Hurricane Sports Agreement (00054674).DOCX Exhibit 10.20 HURRICANE Marketing & Sponsorship Contract MARKETING & SPONSORSHIP AGREEMENT THIS MARKETING AND SPONSORSHIP AGREEMENT ("Agreement") is made and entered as of the 1st day of May, 2012 between SUNPEAK VENUTRES INC. ("Sponsor") and HURRICANE SPORTS PROPERTIES, LLC, a Missouri limited liability company qualified to do business in the St

August 14, 2012 EX-10.19

On Air – WTOP

EX-10.19 9 f10q063012ex10z19.htm EXHIBIT 10.19 PULSE ADVERTISING AGREEMENT Exhibit 10.19 Pulse Advertising, LLC AGREEMENT This agreement (the “Agreement”) dated as of May 2nd, 2012, is by and between Pulse Advertising LLC (“Pulse Advertising”) 1821 Florida Ave NW, Washington, DC 20009, and Healthcare Distribution Specialists (“Sponsor”), 9337 Fraser Avenue, Silver Spring, MD 20910 with respect to

August 14, 2012 EX-10.11

SUNPEAKS VENTURES, INC. CONVERTIBLE PROMISSORY NOTE

EX-10.11 2 f10q063012ex10z11.htm EXHIBIT 10.11 PROMISSORY NOTE LYSANDER OVERSEAS Exhibit 10.11 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY (A)

August 14, 2012 EX-10.17

2012 VENDOR PARTICIPATION Binding Letter of Commitment

Exhibit 10.17 WALGREENS 2012 VENDOR PARTICIPATION Binding Letter of Commitment 4/18/12 This binding letter of commitment ("Letter of Commitment") is by and among Dayton Professional Baseball Club, LLC ("DPB"), the owner of the Dayton Dragons professional baseball team ("Team"}, Walgreens ("Walgreens"), and Health Care Distribution Specialists / Clotamin. (?Vendor"). The term of this Letter of Comm

August 14, 2012 EX-10.18

CBS Radio Inc.

EX-10.18 8 f10q063012ex10z18.htm EXHIBIT 10.18 WFAN CBS RADIO AGREEMENT Exhibit 10.18 CBS Radio Inc. AGREEMENT This agreement (the “Agreement”) dated as of April 26th, 2012, is by and between CBS Radio d/b/a WFAN 660AM (“CBS Radio”) 345 Hudson Street 10th Floor, New York, NY 10014, and Healthcare Distribution Specialists ("Sponsor"). 9337 Fraser Avenue, Silver Spring, MD 20910 with respect to adve

August 3, 2012 S-8

- AUGUST 2, 2012 FORM S-8

S-8 1 s8080212s8.htm AUGUST 2, 2012 FORM S-8 As filed with the Securities and Exchange Commission on August 3, 2012 Registration No. 333- U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Sunpeaks Ventures, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada 27-0777112 (State or Other Jurisdiction of Incor

August 3, 2012 8-K/A

Financial Statements and Exhibits, Other Events - FORM 8-K/A CURRENT REPORT

Form 8-K/A Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

August 3, 2012 EX-4.2

SUNPEAKS VENTURES, INC. 2012 Omnibus Stock Grant and Option Plan INCENTIVE STOCK OPTION AGREEMENT

EX-4.2 3 s8080212ex4z2.htm SUNPEAKS 2012 FORM OF NON STATUTORY STOCK OPTION AGREEMENT (00055157).DOC Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR IF THE C

August 3, 2012 EX-4.1

SUNPEAKS VENTURES, INC. 2012 OMNIBUS STOCK GRANT AND OPTION PLAN TABLE OF CONTENTS Page SECTION 1 PURPOSE` 4 SECTION 2 DEFINITIONS 4 a “Award” 4 b “Board of Directors” 4 c “Change in Control” 4 d “Code” 4 e “Committee” 4 f “Common-Law Employee” 4 g “

Exhibit 4.1 Omnibus Stock Grant Exhibit 4.1 SUNPEAKS VENTURES, INC. 2012 OMNIBUS STOCK GRANT AND OPTION PLAN 1 TABLE OF CONTENTS Page SECTION 1 PURPOSE` 4 SECTION 2 DEFINITIONS 4 a “Award” 4 b “Board of Directors” 4 c “Change in Control” 4 d “Code” 4 e “Committee” 4 f “Common-Law Employee” 4 g “Company” 4 h “Employee” 4 i “Exchange Act” 4 j “Exercise Price” 4 k “Fair Market Value” 5 l “Incentive S

August 3, 2012 EX-10.1

ENDORSEMENT AGREEMENT

Exhibit 10.1 Endorsement Agreement Exhibit 10.1 ENDORSEMENT AGREEMENT THIS ENDORSEMENT AGREEMENT (the "Agreement") is dated as of this day of , 2012, but made effective as of February 20, 2012 ("Effective Date") between Healthcare Distribution Specialists LLC ("HDS"), a Delaware corporation, and Paul Silas ("Celebrity), an individual. AGREEMENT 1. Engagement. HDS engages Celebrity and Celebrity he

July 27, 2012 CORRESP

-

SEC Response July 26, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

July 27, 2012 EX-10.16

GENERAL TERMS AND CONDITIONS

Exhibit 10.16 Agreement with NCPA and GNR Exhibit 10.16 AGREEMENT This Agreement (this "Agreement") is made and entered into as of the date signed by the last party to sign below (the "Effective Date"), by and between National Community Pharmacists Association ("NCPA"), with its principal address at 100 Daingerfield Road, Alexandria, Virginia 22314 and Global Nutritional Research, LLC, a Maryland

July 27, 2012 EX-99.2

Unaudited Pro Forma Condensed Combined Financial Statements

Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Statements On February 16, 2012, pursuant to a Share Exchange Agreement (“Exchange Agreement”) dated February 13, 2012, Sunpeaks acquired 100% ownership interest in Healthcare Distribution Specialists LLC (“HDS”), a Delaware limited liability company, in exchange for the issuance of 200,000,000 newly-issued restricted shares of Sunpeaks

July 27, 2012 EX-10.15

AMENDED AND RESTATED ASSET ACQUISITION AGREEMENT AMERISURE PHARMACEUTICALS, LLC, A DELAWARE LIMITED LIABILITY COMPANY GLOBAL NUTRITIONAL RESEARCH, LLC, A MARYLAND LIMITED LIABILITY COMPANY AMENDED AND RESTATED ASSET ACQUISITION AGREEMENT

EX-10.15 4 f8ka071912ex10z15.htm EXHIBIT 10.15 PROMISSORY NOTE WITH EAGLE BANK Exhibit 10.15 AMENDED AND RESTATED ASSET ACQUISITION AGREEMENT BETWEEN AMERISURE PHARMACEUTICALS, LLC, A DELAWARE LIMITED LIABILITY COMPANY AND GLOBAL NUTRITIONAL RESEARCH, LLC, A MARYLAND LIMITED LIABILITY COMPANY AMENDED AND RESTATED ASSET ACQUISITION AGREEMENT This Amended and Restated Asset Acquisition Agreement (th

July 27, 2012 EX-10.17

Global Nutritional Research Business Proposal

EX-10.17 6 f8ka071912ex10z17.htm EXHIBIT 10.17 AGREEMENT WITH NCPA AND GNR Exhibit 10.17 Global Nutritional Research Business Proposal DESCRIPTION This is a binding contract proposal involving the services of Safe Chain Solutions, LLC (service provider) and Global Nutritional Research. These services include but are not limited to warehouse distribution, inventory management, order fulfillment, re

July 27, 2012 8-K/A

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets - FORM 8-K/A AMENDED CURRENT REPORT

FORM 8-K/A Amended Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.

July 27, 2012 EX-99.1

Healthcare Distribution Specialists, Inc. (formerly Amerisure Pharmaceuticals LLC) Financial Statements For the Years Ended December 31, 2011 and 2010 (Adjusted) Page Report of Independent Registered Public Accounting Firm 2 Consolidated Balance Shee

Exhibit 99.1 Healthcare Distribution Specialists, Inc. (formerly Amerisure Pharmaceuticals LLC) Financial Statements For the Years Ended December 31, 2011 and 2010 (Adjusted) Page Report of Independent Registered Public Accounting Firm 2 Consolidated Balance Sheet as of December 31, 2011 and Combined Balance Sheet as of December 31, 2010 3 Consolidated Statement of Operations for the year ended De

July 27, 2012 EX-10.14

PROMISSORY NOTE Principal $200,000.00 Loan Date 08-04-2011 Maturity Loan No 72001 Call / Coll 1766 / U8 Account 7200118427 Officer HC Initials References in the box above are for Lender's use only and do not limit the application of this document to

EX-10.14 3 f8ka071912ex10z14.htm EXHIBIT 10.14 PROMISSORY NOTE WITH EAGLE BANK Exhibit 10.14 PROMISSORY NOTE Principal $200,000.00 Loan Date 08-04-2011 Maturity Loan No 72001 Call / Coll 1766 / U8 Account 7200118427 Officer HC Initials References in the box above are for Lender's use only and do not limit the application of this document to any particular loan or item. Any item above containing "*

July 27, 2012 EX-10.11

SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE

EX-10.11 2 f8ka071912ex10z11.htm EXHIBIT 10.11 SETTLEMENT AGREEMENT WITH WHETU Exhibit 10.11 SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE This settlement Agreement and General Mutual Release (the “Agreement”) is made and entered into as of February 13, 2012, by and between, on the one hand, Sunpeaks Ventures, Inc. a Nevada corporation (“Sunpeaks”) and, on the other hand, Whetu, Inc. (“Holder”).

June 20, 2012 CORRESP

-

SEC Letter THE LEBRECHT GROUP A PROFESSIONAL LAW CORPORATION Brian A. Lebrecht, Esq. Craig V. Butler, Esq. * Admitted only in California* June 20, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Ruairi Regan Re: Sunpeaks Ventures, Inc. (the “Company”) Current Report on Form 8-K Filed February 17, 2012 File No. 000-

June 11, 2012 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

10-Q 1 f10q03311210q.htm MARCH 31, 2012 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to

May 16, 2012 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commission File Number) 27

May 16, 2012 EX-10.1

SUNPEAKS VENTURES, INC. FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE

EX-10.1 2 f8k051612ex10z1.htm EXHIBIT 10.1 FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE Exhibit 10.1 SUNPEAKS VENTURES, INC. FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This First Amendment to Convertible Promissory Note (this “Amendment”) is entered into this 10th day of May, 2012, by and between Sunpeaks Ventures, Inc., a Nevada corporation (the “Company”) and Lysander Overseas, Inc. (the “

May 15, 2012 NT 10-Q

- EXTENSION FOR MARCH 31, 2012 10-Q

Extension for March 31, 2012 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 000-54523 CUSIP NUMBER FORM 12b-25 86765E 202 NOTIFICATION OF LATE FILING . Form 10-K . Form 20-F . Form 11-K X . Form 10-Q . Form 10-D . Form N-SAR . Form N-CSR For period ended: March 31, 2012 . Transition Report on Form 10-K . Transition Report on Form 20-F . Transition Report on For

May 11, 2012 EX-10.1

EX-10.1

EX-10.1 2 f8k051012ex10z1.htm EXHIBIT 10.1 MARKETING AGREEMENT Exhibit 10.1

May 11, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 f8k0510128k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-545

May 8, 2012 CORRESP

-

SEC Response Letter THE LEBRECHT GROUP A Professional Law Corporation Brian A. Lebrecht, Esq. Craig V. Butler, Esq.* Admitted only in California* May 7, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Ruairi Regan Re: Sunpeaks Ventures, Inc. Current Report on Form 8-K Filed February 17, 2012 File No. 000-54523 Dear

May 4, 2012 EX-10.1

EX-10.1

EX-10.1 2 f8k050412ex10z1.htm EXHIBIT 10.1 AGREEMENT Exhibit 10.1

May 4, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commission File Nu

May 2, 2012 EX-10.1

EX-10.1

EX-10.1 2 f8k050112ex10z1.htm EXHIBIT 10.1 AGREEMENT Exhibit 10.1

May 2, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commission File

May 1, 2012 CORRESP

-

May 1, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.

April 25, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54523 (Commission File

April 25, 2012 EX-10.1

EX-10.1

EX-10.1 2 f8k042512ex10z1.htm EXHIBIT 10.1 BINDING LETTER OF COMMITMENT Exhibit 10.1

April 24, 2012 EX-10.1

EX-10.1

Exhibit 10.1 Binding Letter of Commitment Exhibit 10.1

April 24, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 currentreport8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorpora

April 18, 2012 EX-10.2

EX-10.2

Exhibit 10.2 Advertising and Promotion Agreement Exhibit 10.2

April 18, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT

FORM 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

April 18, 2012 EX-10.1

EX-10.1

EX-10.1 2 bindingletterex10z1.htm EXHIBIT 10.1 BINDING LETTER OF COMMITMENT Exhibit 10.1

April 18, 2012 CORRESP

-

CORRESP 1 filename1.htm April 18, 2012 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Rory Reagan Re: Sunpeaks Ventures, Inc. Current Report on Form 8-K Filed February 17, 2012 File No. 000-54523 Dear Mr. Reagan: Per our telephone call on Monday, April 16, 2012, please be advised that this firm is representing Sunpeaks

April 11, 2012 8-K

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT

Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

April 11, 2012 EX-10.1

Exhibit 10.1

Exhibit 10.1 Convertible Promissory Note Exhibit 10.1 2 3 4 5 6 7

April 11, 2012 EX-10.2

Exhibit 10.2

EX-10.2 3 f8k041112ex10z2.htm EXHIBIT 10.2 PASS-THROUGH SPONSORSHIP LETTER AGREEMENT Exhibit 10.2 2 3 4 5 6

April 6, 2012 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 f8k0405128k.htm FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of inco

April 6, 2012 EX-10.2

EX-10.2

Exhibit 10.2

April 6, 2012 EX-10.1

Exhibit 10.1

Exhibit 10.1 Distribution Agreement Exhibit 10.1 Mega Brand Group. 7981 NW 21 Miami Fl 33122 [email protected] Ph: 305 593 5558, fax: 309 593 5859 Castor Castineira. Clotamin/ Winn-Dixie Product authorization (1 item) $ 20.000.00 In Stores DSD, Product Management $ 20.000.00 Total amount $ 40.000.00 · Payment Method , Wire transfer. · Bank, JP Morgan Chase · Address: 10495 NW 12 St, Miam

March 29, 2012 CORRESP

-

SEC Response SUNPEAKS VENTURES, INC. 89337 Fraser Avenue Silver Spring, MD 20370 March 29, 2012 Via EDGAR John Reynolds, Assistant Director U.S. Securities and Exchange Commission Washington, D.C. 20549-0302 Re: Request for Extension to File Response Form 8-K Filed February 17, 2012 File No. 000-54523 Dear Mr. Reynolds, We are in receipt of the comment letter issued by the United States Securities

March 22, 2012 EX-99.2

Sunpeaks Ventures Engages Former All-Star Player and Current Professional Basketball Head Coach as National Clotamin Spokesperson

Exhibit 99.2 Sunpeaks Ventures Engages Former All-Star Player and Current Professional Basketball Head Coach as National Clotamin Spokesperson SILVER SPRING, Md., March 17, 2012 /PRNewswire via COMTEX/ - Sunpeaks Ventures, Inc.'s (pinksheets:SNPK) (the "Company" or "Sunpeaks Ventures") wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") is pleased to announce that they have ent

March 22, 2012 EX-99.1

Sunpeaks Ventures Announces Clotamin available on Walgreens.com

Exhibit 99.1 Sunpeaks Ventures Announces Clotamin available on Walgreens.com SILVER SPRING, MD (03/08/12) Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the “Company” or “Sunpeaks Ventures”) and its wholly owned subsidiary Healthcare Distribution Specialist, LLC (“HDS”) are pleased to announce that Clotamin® is now available on Walgreens.com. "The addition of Walgreens.com is an importa

March 22, 2012 8-K

- FORM 8-K CURRENT REPORT

FORM 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction (Commission File Number

March 6, 2012 EX-99.1

Sunpeaks Ventures Secures Funding of $200,000

Exhibit 99.1 Sunpeaks Initial Funding Exhibit 99.1 Sunpeaks Ventures Secures Funding of $200,000 SILVER SPRING, Md., March 2, 2012 /PRNewswire/ - Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Venutres") is pleased to announce that it has completed an initial financing of $200,000. The proceeds from this financing will be used for general working capital and o

March 6, 2012 8-K

- FORM 8-K CURRENT REPORT

FORM 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction (Commission File Number

February 17, 2012 EX-10.10

SHARE EXCHANGE AGREEMENT

Exhibit 10.10 Share Exchange Agreement Exhibit 10.10 SHARE EXCHANGE AGREEMENT This Share Exchange Agreement, dated as of February 13, 2012 (this “Agreement”) by and among Healthcare Distribution Specialists LLC, a Delaware limited liability company (“HDS”), Mackie Barch, the sole managing member of HDS (the “HDS Managing Member”), Sunpeaks Ventures, Inc., a Nevada corporation (“SNPK”), and Scott B

February 17, 2012 EX-10.13

Exhibit 10.13

Exhibit 10.13 Lease Agreement Exhibit 10.13 Made this 9th day of March, 2011, between Great Spaces, LLC, Landlord, and Amerisure Pharmaceuticals, LLC, Tenant: Witnesseth That the Landlord hereby leases to the Tenant and the Tenant hereby leases from the Landlord the premises located at 9337 Fraser Avenue, Silver Spring, MD, totaling about 2000 square feet of gross floor area. The term of the lease

February 17, 2012 EX-10.09

SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE

Exhibit 10.9 Settlement Agreement Exhibit 10.9 SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE This Settlement Agreement and General Mutual Release (the “Agreement”) is made and entered into as of February 13, 2012, by and between, on the one hand, Sunpeaks Ventures, Inc., a Nevada corporation (“Sunpeaks”) and, on the other hand, Carrillo Huettel, LLP (“Attorney”). Sunpeaks and Attorney are someti

February 17, 2012 EX-10.07

UNSECURED PROMISSORY NOTE

Exhibit 10.7 Promissory Note Exhibit 10.7 UNSECURED PROMISSORY NOTE PRINCIPAL AMOUNT: $110,000 LOAN DATE: May 6, 2011 EXECUTION DATE: July 13, 2011 INTEREST RATE: 10.00% SIMPLE INTEREST BORROWER: SUNPEAKS VENTURES, INC. LENDER: WHETU, INC. PAYMENT: $110,000 DUE ON DEMAND 1. Principal Repayment. For value received, Sunpeaks Ventures, Inc., a Nevada corporation (the “Borrower”) hereby unconditionall

February 17, 2012 EX-99.2

HEALTHCARE DISTRIBUTION SPECIALISTS INC. (formerly Amerisure Pharmaceuticals LLC) (A Development Stage Company) Financial Statements For the Nine Months Ended September 30, 2011 and 2010 (unaudited)

Exhibit 99.2 HEALTHCARE DISTRIBUTION SPECIALISTS INC. (formerly Amerisure Pharmaceuticals LLC) (A Development Stage Company) Financial Statements For the Nine Months Ended September 30, 2011 and 2010 (unaudited) Balance Sheets 2 Statements of Operations 3 Statements of Cash Flows 4 Notes to the Financial Statements 5 HEALTHCARE DISTRIBUTION SPECIALISTS INC. (formerly Amerisure Pharmaceuticals LLC)

February 17, 2012 EX-10.08

SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE

EX-10.08 3 f8k021612ex10z08.htm EXHIBIT 10.8 SETTLEMENT AGREEMENT Exhibit 10.8 SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE This Settlement Agreement and General Mutual Release (the “Agreement”) is made and entered into as of February 13, 2012, by and between, on the one hand, Sunpeaks Ventures, Inc., a Nevada corporation (“Sunpeaks”) and, on the other hand, Scott Beaudette (“Holder”). Sunpeaks

February 17, 2012 EX-10.12

MANAGEMENT AGREEMENT

Exhibit 10.12 Management Agreement Exhibit 10.12 MANAGEMENT AGREEMENT This Management Agreement (the “Agreement”) entered into on February 13, 2012, and made effective as of the 13th day of February, 2012, (the “Effective Date”) by and between Sunpeaks Ventures, Inc., a Nevada corporation (the “Company”) and Mackie Barch (“Mr. Barch”). RECITALS: WHEREAS, Mr. Barch has expertise in the areas of cor

February 17, 2012 8-K

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets - FORM 8-K CURRENT REPORT

FORM 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2012 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54523 27-0777112 (State or other jurisdiction (Commission File Nu

February 17, 2012 EX-21.1

LIST OF SUBSIDIARIES OF SUNPEAKS VENTURES, INC.

EXHIBIT 21.1 List of Subsidiaries EXHIBIT 21.1 LIST OF SUBSIDIARIES OF SUNPEAKS VENTURES, INC. 1. Healthcare Distribution Specialists LLC Jurisdiction of Formation: Names under which business is conducted: State of Delaware Healthcare Distribution Specialists LLC

February 17, 2012 EX-99.1

AMERISURE PHARMACEUTICALS LLC (A Development Stage Company) Financial Statements For the Years Ended December 31, 2010 and 2009

Exhibit 99.1 AMERISURE PHARMACEUTICALS LLC (A Development Stage Company) Financial Statements For the Years Ended December 31, 2010 and 2009 Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Stockholders’ Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM T

February 13, 2012 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 . TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-161985 SUNPEAKS VENTURES, INC. (Exact name of re

December 8, 2011 8-K

Current Report

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2011 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 333-161985 27-0777112 (State or other jurisdiction (Commission File Number) (IRS Employer of I

November 14, 2011 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 quarterlyreport10q.htm FORM 10-Q QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 . TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File N

November 4, 2011 8-K

Current Report

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2011 SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Nevada 333-161985 27-0777112 (State or other jurisdiction (Commission File Number) (IRS Employer of I

November 4, 2011 EX-3.1

AMENDED AND RESTATED ARTICLES OF INCORPORATION Sunpeaks Ventures, Inc., a Nevada Corporation

EX-3.1 2 f8k110311ex3z1.htm EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF Sunpeaks Ventures, Inc., a Nevada Corporation Scott Beaudette hereby certifies that: 1. He is the President of Sunpeaks Ventures, Inc., a Nevada corporation. 2. The Articles of Incorporation of this Corporation are amended and restated in their entirety to read as fol

October 13, 2011 8-A12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 SUNPEAKS VENTURES, INC. (Exact name of registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 SUNPEAKS VENTURES, INC.

October 12, 2011 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2011 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to SUNPEAKS VENTURES, INC. (Exact name of registrant as specified in its charter) Neva

September 28, 2011 NT 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION

NT 10-K 1 nt10k063011nt10k.htm FORM 12B-25 NOTIFICATION OF LATE FILING U.S. SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 333-161985 CUSIP NUMBER FORM 12b-25 86765E103 NOTIFICATION OF LATE FILING X . Form 10-K . Form 20-F . Form 11-K .Form 10-Q . Form 10-D . Form N-SAR . Form N-CSR For period ended: . Transition Report on Form 10-K . Transition Report on Form 20-F . Tra

August 2, 2011 POS AM

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification

July 13, 2011 424B3

SUPPLEMENT NO. 2 DATED JULY 13, 2011 TO PROSPECTUS DATED JANUARY 14, 2011. SUNPEAKS VENTURES, INC.

Filed pursuant to Rule 424(b)(3) Registration No. 333-161985 SUPPLEMENT NO. 2 DATED JULY 13, 2011 TO PROSPECTUS DATED JANUARY 14, 2011. SUNPEAKS VENTURES, INC. The following information supplements the prospectus of Sunpeaks Ventures, Inc. dated January 14, 2011 and is part of the prospectus. This Supplement updates the information presented in the prospectus. Prospective investors should carefull

June 20, 2011 424B3

SUPPLEMENT NO. 1 DATED JUNE 17, 2011 TO PROSPECTUS DATED JANUARY 14, 2011. SUNPEAKS VENTURES, INC.

Filed pursuant to Rule 424(b)(3) Registration No. 333-161985 SUPPLEMENT NO. 1 DATED JUNE 17, 2011 TO PROSPECTUS DATED JANUARY 14, 2011. SUNPEAKS VENTURES, INC. The following information supplements the prospectus of Sunpeaks Ventures, Inc. dated January 14, 2011 and is part of the prospectus. This Supplement updates the information presented in the prospectus. Prospective investors should carefull

May 16, 2011 EX-10

SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE

Exhibit 10.06 SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE This Settlement Agreement and General Mutual Release (?Agreement?) is made and entered into as of this 5th day of May, 2011, by and between Sunpeaks Ventures Corp. (?SPKS?) and Habana Investments (?Holder?). SPKS and HOLDER are sometimes referred to herein as ?Party? or ?Parties?. RECITALS A. Whereas, on various dates commencing on June

May 16, 2011 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 . TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-161985 SUNPEAKS VENTURES, INC. (Exact name of regis

May 16, 2011 EX-10

SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE

Exhibit 10.05 SETTLEMENT AGREEMENT AND GENERAL MUTUAL RELEASE This Settlement Agreement and General Mutual Release (?Agreement?) is made and entered into as of this 5th day of May, 2010, by and between Sunpeaks Ventures Corp. (?SPKS?) and Blue Lagoon Capital (?Holder?). SPKS and HOLDER are sometimes referred to herein as ?Party? or ?Parties?. RECITALS A. Whereas, on or about June 25, 2009, the SPK

February 3, 2011 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X .QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010 .TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number 333-161985 SUNPEAKS VENTURES, INC. (Name of small business iss

January 14, 2011 424B3

SUNPEAKS VENTURES, INC. #106, 505 19 Ave SW Calgary, Alberta, T2S 0E4 Canada (403) 540-5277 700,000 shares of common stock

Filed pursuant to Rule 424 (b)(3) Registration No. 333-161985 PROSPECTUS SUNPEAKS VENTURES, INC. #106, 505 19 Ave SW Calgary, Alberta, T2S 0E4 Canada (403) 540-5277 700,000 shares of common stock We are offering up to 700,000 shares of our common stock in a direct public offering with an offering price of $0.06 per share. This offering shall be conducted without any involvement of underwriters or

January 14, 2011 424B3

SUNPEAKS VENTURES, INC. #106, 505 19 Ave SW Calgary, Alberta, T2S 0E4 Canada (403) 540-5277 1,700,000 shares of common stock

Filed pursuant to Rule 424 (b)(3) Registration No. 333-161985 PROSPECTUS SUNPEAKS VENTURES, INC. #106, 505 19 Ave SW Calgary, Alberta, T2S 0E4 Canada (403) 540-5277 1,700,000 shares of common stock Our existing shareholders are offering for sale, 1,700,000 shares of common stock. The offering price is $0.06 per share for those being sold by current shareholders. All dealers that effect transaction

January 7, 2011 CORRESP

Footnotes

Acceleration Request January 7, 2011 VIA EDGAR Doug Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

December 8, 2010 CORRESP

SUNPEAKS VENTURES, INC.

SUNPEAKS VENTURES, INC. December 8, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington DC 20549 Re: Sunpeaks Ventures, Inc. File No.: 333-161985 SEC Comment letter dated December 2, 2010 Dear Mr. Brown: Sunpeaks Ventures, Inc. (the ?Company?), a Nevada corporation, has received and reviewed your letter of December 2, 2010, pertaining

December 8, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified i

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

November 12, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 9 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 9 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

November 12, 2010 CORRESP

FORM S-1

November 11, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

November 10, 2010 CORRESP

_________________________________________________________________________ #106, 505 19 Ave SW | Calgary, Alberta, T2S 0E4 | Can ada | 403-540-5277

November 9, 2010 VIA EDGAR Doug Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

November 8, 2010 CORRESP

_________________________________________________________________________ #106, 505 19 Ave SW | Calgary, Alberta, T2S 0E4 | Canada | 403-540-5277

November 8, 2010 VIA EDGAR Doug Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

October 22, 2010 CORRESP

FORM S-1

October 22, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

October 22, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

August 13, 2010 CORRESP

FORM S-1

August 12, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

August 13, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 7 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 7 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

July 20, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

S-1/A 1 sunpeakss1a6.htm FORM S-1/A REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (P

July 19, 2010 CORRESP

FORM S-1

July 14, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

June 14, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 5 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 5 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

June 14, 2010 CORRESP

FORM S-1

June 14, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

May 25, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

May 24, 2010 CORRESP

FORM S-1

May 20, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

May 5, 2010 EX-10

EX-10

Exhibit 10.4

May 5, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1382 (Primary Standard Industrial Classification Code Number) N/A

May 5, 2010 CORRESP

FORM S-1

SEC Response Letter April 28, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.

March 2, 2010 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

S-1/A 1 sunpeakss1a2.htm FORM S-1/A2 REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1311 (

March 2, 2010 CORRESP

SUNPEAKS VENTURES, INC.

SUNPEAKS VENTURES, INC. February 26, 2010 Douglas Brown Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington DC 20549 Re: Sunpeaks Ventures, Inc. File No. 333-161985 SEC Comment letter dated January 21, 2010 Dear Mr. Brown: Sunpeaks Ventures, Inc. (the “Company”), a Nevada corporation, is pleased advise you that we have received and reviewed your letter o

December 30, 2009 CORRESP

SUNPEAKS VENTURES, INC.

SUNPEAKS VENTURES, INC. December 30, 2009 Anne Nguyen Parker Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington DC 20549 Re: Sunpeaks Ventures, Inc. File No. 333-161985 SEC Comment letter dated October 14, 2009 Dear Ms. Parker: Sunpeaks Ventures, Inc. (the ?Company?), a Nevada corporation, is pleased advise you that we have received and reviewed your le

December 30, 2009 EX-10

MANAGEMENT AGREEMENT

Exhibit 10.3 MANAGEMENT AGREEMENT This Management Agreement (the ?Agreement?) is made effective as of the 25th day of June, 2009, by and between Sunpeaks Ventures, Inc., a Nevada corporation (the ?Company?) and Scott Beaudette (?Mr. Beaudette?). RECITALS: WHEREAS, Mr. Beaudette has expertise in the areas of corporate management, finance, investment, acquisitions and other matters relating to the b

December 30, 2009 S-1/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: 333-161985 SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1000 (Primary Standard Industrial Classification Code Number) N/A

September 18, 2009 EX-10

PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (Subscribers Resident Outside of the United States)

Exhibit 10.1 THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?1933 ACT?). NONE OF THE SECURITIES TO WHICH THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE ?AGREEMENT?) RELATES HAVE BEEN REGIS

September 18, 2009 EX-10

CONVERTIBLE PROMISSORY NOTE

Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE CO

September 18, 2009 EX-3

ARTICLES OF INCORPORATION Sunpeaks Ventures, Inc. a Nevada Corporation ARTICLE 1. Company Name

Exhibit 3.1 ARTICLES OF INCORPORATION OF Sunpeaks Ventures, Inc. a Nevada Corporation ARTICLE 1. Company Name 1.1 The name of this corporation is Sunpeaks Ventures, Inc. ARTICLE 2. Duration 2.1 The corporation shall continue in existence perpetually unless sooner dissolved according to law. ARTICLE 3. Purpose 3.1 The purpose for which the corporation is organized is to engage in any lawful activit

September 18, 2009 S-1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: ____________ SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Commission File Number: SUNPEAKS VENTURES, INC. (Exact name of small Business Issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 1000 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identifica

September 18, 2009 EX-3

SUNPEAKS POWER CORPORATION (A Nevada Corporation) ARTICLE I

Exhibit 3.2 BYLAWS OF SUNPEAKS POWER CORPORATION (A Nevada Corporation) ARTICLE I OFFICES 1.01 Principal Offices. The Board of Directors shall fix the location of the principal executive office of the Corporation at any place within or outside the State of Nevada. If the principal executive office is located outside the State and the Corporation has no principal office in Nevada, the Board of Dire

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista